• Introduced
    Jan 14, 2026
  • Passed Senate
    Feb 10, 2026
  • Passed House
    Feb 24, 2026
  • Became Law
SB 641
Virginia Senate Bill
Did you know we offer free bill tracking in Congress and 50 states, AI tools to streamline your work, and a great mobile app? Sign up here
Office-based buprenorphine treatment; Board of Medicine to amend regulations.
Last Action See all actions
Senate • Feb 26, 2026: Signed by President
Latest Bill Text See all bill texts

Summary

Comments on SB 641

Tweets

Whip Lists

Sponsors
Votes
YES: 98

NO: 0

    NOT VOTING: 1

    Actions
    • Feb 26, 2026 | Senate
      • Signed by President
    • Feb 26, 2026 | House
      • Signed by Speaker
    • Feb 26, 2026 | Senate
      • Enrolled
    • Feb 24, 2026 | House
      • Read third time
      • Passed House Block Vote (98-Y 0-N 0-A)
    • Feb 23, 2026 | House
      • Read second time
    • Feb 19, 2026 | House
      • Reported from Health and Human Services (21-Y 0-N)
    • Feb 13, 2026 | House
      • Placed on Calendar
      • Read first time
      • Referred to Committee on Health and Human Services
    • Feb 10, 2026 | Senate
      • Read third time and passed Senate Block Vote (40-Y 0-N 0-A)
    • Feb 09, 2026 | Senate
      • Read second time
      • Engrossed by Senate Block Vote (Voice Vote)
    • Feb 06, 2026 | Senate
      • Rules suspended
      • Constitutional reading dispensed Block Vote (on 1st reading) (39-Y 0-N 0-A)
      • Passed by for the day Block Vote (Voice Vote)
      • Passed by for the day
    • Feb 05, 2026 | Senate
      • Reported from Education and Health (14-Y 0-N)
    • Jan 30, 2026 | Senate
      • Assigned Education sub: Health Professions
    • Jan 21, 2026 | Senate
      • Fiscal Impact Statement from Department of Planning and Budget (SB641)
    • Jan 14, 2026 | Senate
      • Prefiled and ordered printed; Offered 01-14-2026 26104754D
      • Referred to Committee on Education and Health